Tagged with

Hong Kong Since we last covered Hong Kong in Summer 2023, the territory’s regulatory landscape has taken a major step towards its long-term goal of establishing a full regulatory authority. Having previously required approvals from two separate regulatory authorities in other countries or regions (such as the FDA in the US, the…

Hong Kong It has been an extremely challenging couple of years for Hong Kong’s financial sector, including for the wealth of biotech companies listed in the city, but fundamentals remain strong, and the green shoots of recovery are starting to be seen.   While biotech has historically been a high-risk, high-reward sector,…

Hong Kong Hong Kong boasts some of Asia’s finest universities, with five ranking in the global top 100, and its two medical schools – at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK) – sitting in the global top 40. While this academic prowess produces globally…

Hong Kong Hong Kong needs to capitalise on its strong fundamentals to establish itself as a clinical research hotspot within APAC and support its transition into China’s innovation and technology hub. Does a new one-stop-shop for clinical trials across the Greater Bay Area hold the key?   Clinical trial numbers are skyrocketing…

Hong Kong Billed as China’s attempt to create an economic powerhouse to rival Silicon Valley, ‘The Greater Bay Area’ is a mega-region that includes nine cities in Guangdong province plus the Special Administrative Regions of Hong Kong and Macau. Since its launch in 2017, the GBA has worked to integrate these cities…

APAC A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest its China neurology and allergy business for USD 680 million; and Pfizer, AstraZeneca and Novartis investing in Singaporean manufacturing.  …

China Olivier Dessajan, CEO of Colisée China and Co-President of the French Healthcare Alliance, discusses Colisée’s long-term investment strategies in China, the challenges of navigating the local regulatory environment, and the importance of French-Chinese healthcare collaborations.   French companies are committed to the Chinese market, offering superior products and solutions to…

Saudi Arabia Saudi Arabia – by many measures the cultural, social, and economic epicentre of the Arab and Islamic worlds – is currently undergoing a once-in-a-lifetime transfiguration. The country’s ‘Vision 2030’ transformation plan has not only been radically reshaping the national economy and reducing its dependence on petroleum revenues but has also…

Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries.   We must work together to sustain a healthy and competitive market, ensuring that the generic…

Mexico David López García, a pharma industry executive and rare disease expert, discusses the challenges and advancements in treating rare diseases in Mexico. He highlights the importance of public-private partnerships and the growing interest from industry in the rare disease field.   Every day is an opportunity to make a difference…

China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…

Mexico Stendhal Pharma operates with an “unlimited pipeline” approach by forming strategic alliances with global pharmaceutical companies that lack a presence in Latin America. Rodrigo Ruiz Mingramm explains how, as companies reconsider their direct presence in Latin America due to political and socio-economic uncertainties, Stendhal’s model is becoming more appealing, and…